Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Income from Continuing Operations: 2019-2025

Historic Income from Continuing Operations for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to -$8.8 million.

  • Benitec Biopharma's Income from Continuing Operations fell 90.10% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 78.26%. This contributed to the annual value of -$38.5 million for FY2025, which is 78.26% down from last year.
  • Per Benitec Biopharma's latest filing, its Income from Continuing Operations stood at -$8.8 million for Q2 2025, which was up 39.37% from -$14.5 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Income from Continuing Operations ranged from a high of -$3.5 million in Q1 2022 and a low of -$14.5 million during Q1 2025.
  • For the 3-year period, Benitec Biopharma's Income from Continuing Operations averaged around -$6.9 million, with its median value being -$5.5 million (2023).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first increased by 11.79% in 2024, then tumbled by 250.11% in 2025.
  • Over the past 5 years, Benitec Biopharma's Income from Continuing Operations (Quarterly) stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then dropped by 23.38% to -$6.9 million in 2023, then crashed by 43.98% to -$10.0 million in 2024, then plummeted by 90.10% to -$8.8 million in 2025.
  • Its Income from Continuing Operations stands at -$8.8 million for Q2 2025, versus -$14.5 million for Q1 2025 and -$10.0 million for Q4 2024.